Biogen (BIIB) debt: $6.3B
Biogen had $6.3B of long-term debt on Dec 31, 2025, including the part due within a year, up 38.3% from $4.5B a year earlier.
From Biogen's filings with the SEC · Read the filing · BIIB stock page
Biogen debt by year
#265 of 2,129 US companies by debt · See the full ranking
| Year ended | Debt | Change |
|---|---|---|
| Dec 31, 2025 | $6.3B | +38% |
| Dec 31, 2024 | $4.5B | -33% |
| Dec 31, 2023 | $6.8B | +8% |
| Dec 31, 2022 | $6.3B | +0% |
| Dec 31, 2021 | $6.3B | – |
Debt of similar companies
Companies in the same industry as Biogen, by SEC industry code, with the closest debt. Each name opens the same page for that company.
| Company | Debt, latest year | Year ended |
|---|---|---|
| Amgen | $54.6B | Dec 31, 2025 |
| Gilead Sciences | $24.9B | Dec 31, 2025 |
| Biogen | $6.3B | Dec 31, 2025 |
| Halozyme Therapeutics | $2.1B | Dec 31, 2025 |
| Qiagen | $1.7B | Dec 31, 2025 |
| Moderna | $590M | Dec 31, 2025 |
| Repligen | $542M | Dec 31, 2025 |
Questions and answers
What is Biogen's debt?
Biogen had $6.3B of long-term debt on Dec 31, 2025, including the part due within a year, up 38.3% from $4.5B a year earlier.
Numbers as reported in Biogen's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology